Skip to main content

Table 2 Summary of combination indices from MTT cytotoxicity studies for concurrent bortezomib and RAM2061 treatment

From: Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Fa

ALMC-2

JJN3

MM.1S

RPMI

0.3

1.81

1.22

1.45

1.36

0.5

1.95

1.25

1.5

1.37

0.75

2.2

1.35

1.58

1.38

  1. Cells were incubated with varying concentrations of RAM2061 and/or bortezomib. RAM2061 and bortezomib were added at the beginning of the 48-h incubation period (concurrent). Isobologram analysis was performed, and combination indices were determined. Combination indices > 1 are considered antagonistic in nature